TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21592728

Group type: EXPERIMENTAL
Intervention: Crestal sinus elevation using the new water lift system
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lateral sinus elevation with piezosurgery
Number of subjects: 50
Study: 18837799

Group type: EXPERIMENTAL
Intervention: Weight loss (n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Weight maintenance (n = 15)
Number of subjects: 35
Study: 17062959

Group type: EXPERIMENTAL
Intervention: Stepwise segmental pulmonary vein isolation (SPVI)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI)
Number of subjects: 110
Study: 15648667

Group type: EXPERIMENTAL
Intervention: Microcellular rubber insole footwear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive footwear
Number of subjects: 0
Study: 10931123

Group type: EXPERIMENTAL
Intervention: Theophylline (600 mg/24 h for 2 weeks, then 900 mg/24 h for 2 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 21
Study: 9048676

Group type: EXPERIMENTAL
Intervention: 1 year of treatment with AEDs
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 3 years of treatment with AEDs
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 244
Study: 8244814

Group type: EXPERIMENTAL
Intervention: Palladium-103 (Pd-103) seeds
Number of subjects: 15

Group type: COMPARATOR
Intervention: Iodine-125 (I-125) seeds
Number of subjects: 15
Study: 2942844

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice a day
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 106
Study: 31170623

Group type: EXPERIMENTAL
Intervention: 100 mg niacin
Number of subjects: 124

Group type: COMPARATOR
Intervention: 100 mg sugar pill (placebo)
Number of subjects: 124
Study: 28517999

Group type: EXPERIMENTAL
Intervention: Group I (ambulated before and during hypobaric exposure)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no ambulation)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Group II (ambulated only before hypobaric exposure)
Number of subjects: 107
Study: 25777290

Group type: EXPERIMENTAL
Intervention: jollab (15ml, t.i.d., four weeks, orally)
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo (15ml, t.i.d., four weeks, orally)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: jollab
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study: 23125437

Group type: EXPERIMENTAL
Intervention: Emergency nurse-initiated intervention based on the 5A's framework (Ask-Advise-Assess-Assist-Arrange)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Intervention period
Number of subjects: 789

Group type: COMPARATOR
Intervention: Preintervention period
Number of subjects: 789
Study: 22073146

Group type: EXPERIMENTAL
Intervention: Vitamin D (5000 IU cholecalciferol, one capsule daily for six weeks)
Number of subjects: 128
Study: 20205028

Group type: EXPERIMENTAL
Intervention: Intervention group (school-based intervention programme)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study: 17911991

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 184

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 184
Study: 15841817

Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 3 months
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 6 months
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 18 months
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis with 5-year caries increment as dependent variable
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Preventive treatments provided during the 5-year interval
Number of subjects: 105
Study: 11532385

Group type: EXPERIMENTAL
Intervention: SR 57227A (2.5, 5, 10, 20, 40 mg o.d. and 20 mg b.i.d.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9661091

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 31
Study: 8089287

Group type: EXPERIMENTAL
Intervention: Topical 5% doxepin cream
Number of subjects: 270

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 270
Study: 3378662

Group type: EXPERIMENTAL
Intervention: Tyrothricin rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexetidine rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrogen peroxide rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol rinse
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lozenge with 4 mg tyrothricin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lozenge with 10 mg tyrothricin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Parafilm
Number of subjects: 12
Study: 31383435

Group type: EXPERIMENTAL
Intervention: Sweet almond syrup
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 50
Study: 28474076

Group type: EXPERIMENTAL
Intervention: Special health training and various related health education activities for a period of 1 year
Number of subjects: 330

Group type: COMPARATOR
Intervention: No special health education and behavior intervention
Number of subjects: 330
Study: 26728648

Group type: EXPERIMENTAL
Intervention: Hydrocodone ER (30-90 mg every 12 hours)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Number of subjects: 625
Study: 23439744

Group type: EXPERIMENTAL
Intervention: Sitagliptin with metformin (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin)
Number of subjects: 56
Study: 21639998

Group type: EXPERIMENTAL
Intervention: Diluents A (50% glycerin and water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diluents B (0.4% phenol and water)
Number of subjects: 30
Study: 18338161

Group type: EXPERIMENTAL
Intervention: Personal formulary training (PF)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Existing formulary training (EF)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 583
Study: 17112371

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided cannulation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 450
Study: 12600402

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural self-esteem intervention as an adjunct to treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 10699514

Group type: EXPERIMENTAL
Intervention: Lidocaine administered via Combitube (2.0 mg/kg, diluted with 0.9% saline to a minimum total volume of 10 mL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Endotracheal tube administration of lidocaine (2.0 mg/kg)
Number of subjects: 27
Study: 9175114

Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning with a 1000 Hz tone as the conditioning stimulus and a corneal airpuff as the unconditioned stimulus
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Eyeblink conditioning
Number of subjects: 2

Group type: COMPARATOR
Intervention: Subjects who failed to show eyeblink conditioning
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Vagal activity (measured by the power associated with the respiratory peak in the heart rate spectrum)
Number of subjects: 2
Study: 8380131

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CAP chemotherapy plus radiotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: CAP chemotherapy
Number of subjects: 130
Study: 6325612

Group type: EXPERIMENTAL
Intervention: Extraneous conversation used as a distractor during skill demonstration of intramuscular injections (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No verbal distraction during skill demonstration (control group)
Number of subjects: 50
Study: 31074654

Group type: EXPERIMENTAL
Intervention: Passive heat therapy (PHT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-intensity continuous training (MICT)
Number of subjects: 20
Study: 30684325

Group type: EXPERIMENTAL
Intervention: Metformin and pioglitazone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Metformin and sulphonylureas
Number of subjects: 95
Study: 27002445

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 342
Study: 25304365

Group type: EXPERIMENTAL
Intervention: Performance-based financing combined with community-based health insurance and pro-poor targeting
Number of subjects: 21
Study: 20064698

Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM) training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control training (irrelevant reaction-time test)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall treatment success and relapse up to 3 months after the intervention
Number of subjects: 43
Study: 16282296

Group type: EXPERIMENTAL
Intervention: Sitamaquine 1.75 mg/kg/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.0 mg/kg/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sitamaquine 2.5 mg/kg/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sitamaquine 3.0 mg/kg/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall (all doses)
Number of subjects: 95
Study: 9875118

Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 12
Study: 7526528

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation alone and in combination with androgen deprivation therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (radiation, chemotherapy, androgen deprivation)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prostate cancer-specific survival
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clinically detectable recurrence (excluding PSA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Recurrence (including PSA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Local control
Number of subjects: 76

Group type: COMPARATOR
Intervention: Surgical morbidity
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Morbidity of adjuvant therapy
Number of subjects: 76
Study: 2917584

Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg t.d.s.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Terbutaline 2.5 mg t.d.s. (following chronic therapy)
Number of subjects: 6
Study: 241600

Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: 4.8 g. aspirin daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac tablets
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3 g. alclofenac capsules
Number of subjects: 76
Study: 29313279

Group type: EXPERIMENTAL
Intervention: ABT-767 (400 mg BID)
Number of subjects: 93
Study: 27031854

Group type: EXPERIMENTAL
Intervention: EC-Doc
Number of subjects: 1364

Group type: COMPARATOR
Intervention: FEC120
Number of subjects: 1364
Study: 24645907

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Deficient nutrition
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Hearing loss in both ears
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 333
Study: 22668678

Group type: EXPERIMENTAL
Intervention: Mendelsohn maneuver
Number of subjects: 18
Study: 20369533

Group type: EXPERIMENTAL
Intervention: Hidden tension suture with absorbable thread (test group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Common interrupted suture (control group)
Number of subjects: 203
Study: 18778948

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 120

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 120
Study: 16137951

Group type: EXPERIMENTAL
Intervention: Soy protein supplement containing isoflavones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food enriched with isoflavones
Number of subjects: 0
Study: 12897218

Group type: EXPERIMENTAL
Intervention: Single dose of retinol (209 micro mol) supplementation to mothers
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 150
Study: 10383510

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg or 30 mg
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 8682467

Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 ml applied to the liver cut surface)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 77
Study: 2067772

Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Peripheral administration of oxytocin
Number of subjects: 100
Study: 6602542

Group type: EXPERIMENTAL
Intervention: Rifampin prophylaxis (20 mg/kg/day in two doses for four days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30297258

Group type: EXPERIMENTAL
Intervention: 5min-TI method for data selection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 5min-SS-4P method for data selection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 5min-SS-2P method for data selection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: AUC method for data analysis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 5min-SS-4P method for data analysis
Number of subjects: 44
Study: 29269325

Group type: COMPARATOR
Intervention: 9-valent HPV vaccine
Number of subjects: 5312

Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 5312
Study: 27965491

Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RGIC)
Number of subjects: 80
Study: 24490775

Group type: EXPERIMENTAL
Intervention: High fluid overload (FO > 2.5 L) group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Low fluid overload (FO ≤ 2.5 L) group
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Reduction in fluid overload over 3 months by strict fluid management plan
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Correlation analysis of HRV indices with hydration status indices
Number of subjects: 69
Study: 23072576

Group type: EXPERIMENTAL
Intervention: Early surgical intervention within 12 hours for TICH
Number of subjects: 840

Group type: COMPARATOR
Intervention: Conservative treatment for TICH
Number of subjects: 840
Study: 20593910

Group type: EXPERIMENTAL
Intervention: Propranolol 3 mg/kg/day (adjusted to 2 mg/kg/day after first follow-up)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sodium valproate 30 mg/kg/day (adjusted to 15 mg/kg/day after first follow-up)
Number of subjects: 63
Study: 18055993

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) and cyclosporine (CsA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bone marrow transplantation from an HLA‐matched unrelated donor
Number of subjects: 44
Study: 16181017

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study: 11904111

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg daily (high dose)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Fluconazole 200 mg daily (low dose)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg daily (maintenance therapy)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Clotrimazole troches 10 mg 4 times daily (maintenance therapy)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Fluconazole (maintenance therapy)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Clotrimazole (maintenance therapy)
Number of subjects: 253
Study: 10588452

Group type: COMPARATOR
Intervention: T-cell responses to GAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: T-cell responses to CVB4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between T-cell responses to GAD and CVB4 in IDDM patients
Number of subjects: 0
Study: 7598917

Group type: EXPERIMENTAL
Intervention: Intranasal alfentanil 0.54 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous (IV) alfentanil 0.54 mg
Number of subjects: 10
Study: 2195085

Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: cognitive‐behavioral therapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: imipramine plus clinical management
Number of subjects: 250

Group type: COMPARATOR
Intervention: pill placebo plus clinical management
Number of subjects: 250
Study: 665595

Group type: EXPERIMENTAL
Intervention: Sulfonamides
Number of subjects: 201

Group type: COMPARATOR
Intervention: Decongestants
Number of subjects: 201
Study: 31267366

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 μg, two inhalations per dose, twice-daily
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol dry powder inhaler (UV DPI) 62.5/25 μg, one inhalation, once-daily
Number of subjects: 1119
Study: 28991907

Group type: EXPERIMENTAL
Intervention: Healthy Start intervention (15 months duration)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 307
Study: 25387363

Group type: EXPERIMENTAL
Intervention: ARA 290 (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24192466

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 30
Study: 20706141

Group type: EXPERIMENTAL
Intervention: AEP group
Number of subjects: 220

Group type: COMPARATOR
Intervention: OAA/S group
Number of subjects: 220
Study: 21206354

Group type: EXPERIMENTAL
Intervention: Theory-based instructional manual and Thera-Band resistive bands for upper-body resistance exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard exercise recommendations (wait-list control)
Number of subjects: 40
Study: 17699311

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d (EPL50)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone 100 mg/d (EPL100)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/d (EPL50) and Eplerenone 100 mg/d (EPL100)
Number of subjects: 0
Study: 15515746

Group type: EXPERIMENTAL
Intervention: I‐131 uptake (IU)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: I‐131 whole body scintigraphy (WBS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Technetium scintigraphy (TS)
Number of subjects: 62
Study: 11165408

Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1200 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Gemcitabine + vinorelbine (gemcitabine at 1000 mg/m² and vinorelbine at 25 mg/m² on days 1 and 8, every 3 weeks)
Number of subjects: 49
Study: 9644706

Group type: EXPERIMENTAL
Intervention: Minimal smoking‐cessation intervention (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (n = 14)
Number of subjects: 28
Study: 7639368

Group type: EXPERIMENTAL
Intervention: Epidural morphine (5 mg in 10 mL of 0.9% saline)
Number of subjects: 20
Study: 3297940

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (Wellferon)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study: 31298927

Group type: COMPARATOR
Intervention: Dorsiflexion closing wedge metatarsal osteotomy (DCWMO)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Osteochondral autologous transplantation (OAT)
Number of subjects: 27
Study: 30820008

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of Growth Hormone and Aromatase Inhibitors (AI/GH)
Number of subjects: 76
Study: 26479711

Group type: EXPERIMENTAL
Intervention: Probiotic beverage (L. casei, 10^11 colony-forming units·day‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 24447510

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the gluteus medius tendon (GMT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the gluteus medius muscle (GMM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the adductor longus tendon (ALT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections into GMT and GMM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the ALT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 16
Study: 23225029

Group type: EXPERIMENTAL
Intervention: Standardized assessment incorporating the Clinician Administered PTSD Scale and the World Health Organization Disability Assessment Schedule‐II
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual disability examiner practices for PTSD
Number of subjects: 384
Study: 19737594

Group type: EXPERIMENTAL
Intervention: HEMA/water primer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: HEMA/acetone primer
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Free surface evaporation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dentine cubes evaporation
Number of subjects: 5
Study: 18198311

Group type: EXPERIMENTAL
Intervention: Jump rope exercise training (40 min/d, 5 d/wk for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 26